SEARCH

SEARCH BY CITATION

References

  • 1
    Stöhr K, Kieny M, Wood D. Influenza pandemic vaccines: how to ensure a low-cost, low-dose option. Nat Rev Micro 2006; 4:565566.
  • 2
    World Health Organization. Avian influenza assessing the pandemic threat, 2005. Available at: http://www.who.int/crs/desease/infuenza/WHO_CDS_2005_29/en/.
  • 3
    Murray CJ, Lopez AD, Chin B, Feehan D, Hill KH. Estimation of potential global influenza mortality on the basis of vital registry data from the 1918–20 pandemic: a quantitative analysis. Lancet 2006; 368:22112218.
  • 4
    Wilschut JC, McElhaney JE, Palache AM. Vaccination: cornerstone of influenza control. In: WilschutJC, McElhaneyJE, PalacheAM, eds. Influenza. Amsterdam: Elsevier, 2006; 150183.
  • 5
    Stegmann T, Morselt HW, Booy FP, Van Breemen JF, Scherphof G, Wilschut J. Functional reconstitution of influenza virus envelopes. EMBO J 1987; 6:26512659.
  • 6
    Huckriede A, Bungener L, Daemen T, Wilschut J. Influenza virosomes in vaccine development. Meth Enzymol 2003; 373:7491.
  • 7
    Stephenson I, Nicholson KG, Glück R et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 2003; 362:19591966.
  • 8
    Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 2004; 103:163171.
  • 9
    Hehme N, Engelmann H, Kunzel W, Neumeier E, Sanger R. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol (Berl) 2002; 191:203208.
  • 10
    Bresson J, Perronne C, Launay O et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006; 367:16571664.
  • 11
    Lin J, Zhang J, Dong X et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006; 368:991997.
  • 12
    De Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 2003; 115:6373.
  • 13
    Coutelier JP, Van Der Logt JT, Heessen FW, Warnier G, Van Snick J. IgG2a restriction of murine antibodies elicited by viral infections. J Exp Med 1987; 165:6469.
  • 14
    Hocart MJ, Mackenzie JS, Stewart GA. The immunoglobulin G subclass response of mice to influenza A virus: the effect of mouse strain, and the neutralizing abilities of individual protein A-purified subclass antibodies. J GenVirol 1998; 70:24392448.
  • 15
    Fazekas G, Rosenwirth B, Dukor P, Gergely J, Rajnavolgyi E. IgG isotype distribution of local and systemic immune responses induced by influenza virus infection. Eur J Immunol 1994; 24:30633067.
  • 16
    Huber VC, Lynch JM, Bucher DJ, Le J, Metzger DW. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 2001; 166:73817388.
  • 17
    Neuberger MS, Rajewsky K. Activation of mouse complement by monoclonal mouse antibodies. Eur J Immunol 1981; 11:10121016.
  • 18
    Heusser CH, Anderson CL, Grey HM. Receptors for IgG: subclass specificity of receptors on different mouse cell types and the definition of two distinct receptors on a macrophage cell line. J Exp Med 1977; 145:13161327.
  • 19
    Gessner JE, Heiken H, Tamm A, Schmidt RE. The IgG Fc receptor family. Ann Hematol 1998; 76:231248.
  • 20
    Mozdzanowska K, Feng J, Eid M, Zharikova D, Gerhard W. Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components. Virology 2006; 352:418426.
  • 21
    Jayasekera JP, Moseman EA, Carroll MC. Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity. J Virol 2007; 81:34873494.
  • 22
    Huber VC, McKeon RM, Brackin MN et al. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 2006; 13:981990.
  • 23
    Brown D, Roman E, Swain S. CD4 T cell responses to influenza infection. Sem Immunol 2004; 16:171177.
  • 24
    Moran TM, Isobe H, Fernandez-Sesma A, Schulman JL. Interleukin-4 causes delayed virus clearance in influenza virus-infected mice. J Virol 1996; 70:52305235.
  • 25
    Moran TM, Park H, Fernandez-Sesma A, Schulman JL. Th2 responses to inactivated influenza virus can be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection. J Infect Dis 1999; 180:579585.
  • 26
    Bot A, Bot S, Bona C. Protective role of gamma interferon during the recall response to influenza virus. J Virol 1998; 72:66376645.
  • 27
    Bot A, Holz A, Christen U et al. Local IL-4 expression in the lung reduces pulmonary influenza-virus-specific secondary cytotoxic T cell responses. Virology 2000; 269:6677.
  • 28
    Thomas PG, Keating R, Hulse-Post DJ, Doherty PC. Cell-mediated protection in influenza infection. Emerg Infect Dis 2006; 12:4854.
  • 29
    Swain S, Agrewala J, Brown D et al. CD4+ T-cell memory: generation and multi-faceted roles for CD4+ T cells in protective immunity to influenza. Immunol Rev 2006; 211:822.
  • 30
    Rowe T, Abernathy RA, Hu-Primmer J et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37:937943.
  • 31
    Bungener L, Huckriede A, De Mare A, De Vries-Idema J, Wilschut J, Daemen T. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine 2005; 23:12321241.
  • 32
    Lutz M, Kukutsch N, Ogilvie A et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999; 223:7792.
  • 33
    Vignali DA. Multiplexed particle-based flow cytometric assays. J Immunol Methods 2000; 243:243255.
  • 34
    Lund JM, Alexopoulou L, Sato A et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A 2004; 101:55985603.
  • 35
    Feili-Hariri M, Falkner D, Morel P. Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy. J Leukocyte Biol 2005; 78:656664.
  • 36
    Barchet W, Blasius A, Cella M, Colonna M. Plasmacytoid dendritic cells: in search of their niche in immune responses. Immunol Res 2005; 32:7583.
  • 37
    Kark JD, Lebiush M, Rannon L, Witztum E, Nili E, Kedem R. The antigenicity of whole virus versus subunit trivalent influenza vaccines – a field trial in the Israel Defence Forces, 1978. Med Microbiol Immunol 1981; 170:5562.
  • 38
    Balkovic ES, Florack JA, Six HR. Immunoglobulin G subclass antibody responses of mice to influenza virus antigens given in different forms. Antiviral Res 1987; 8:151160.
  • 39
    Bernstein DI, Zahradnik JM, DeAngelis CJ, Cherry JD. Clinical reactions and serologic responses after vaccination with whole-virus or split-virus influenza vaccines in children aged 6 to 36 months. Pediatrics 1982; 69:404408.
  • 40
    McElhaney JE, Meneilly GS, Lechelt KE, Beattie BL, Bleackley RC. Antibody response to whole-virus and split-virus influenza vaccines in successful ageing. Vaccine 1993; 11:10551060.
  • 41
    Hovden AO, Cox RJ, Haaheim LR. Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scand J Immunol 2005; 62:3644.
  • 42
    Hovden AO, Cox RJ, Madhun A, Haaheim LR. Two doses of parenterally administered split influenza virus vaccine elicited high serum IgG concentrations which effectively limited viral shedding upon challenge in mice. Scand J Immunol 2005; 62:342352.
  • 43
    Szyszko E, Brokstad K, Cox RJ, Hovden AO, Madhun A, Haaheim LR. Impact of influenza vaccine formulation with a detailed analysis of the cytokine response. Scand J Immunol 2006; 64:467475.
  • 44
    Guermonprez P, Valladeau J, Zitvogel L, Théry C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002; 20:621667.
  • 45
    Shortman K, Liu Y-J. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002; 2:151161.
  • 46
    Lopéz C, Yount J, Moran T. Toll-like receptor-independent triggering of dendritic cell maturation by viruses. J Virol 2006; 80:31283134.
  • 47
    Moser M, Murphy KM. Dendritic cell regulation of TH1–TH2 development. Nat Immunol 2000; 1:199205.
  • 48
    Huang Q, Liu D, Majewski P et al. The plasticity of dendritic cell responses to pathogens and their components. Science 2001; 294:870875.
  • 49
    Asselin-Paturel C, Boonstra A, Dalod M et al. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat Immunol 2001; 2:11441150.
  • 50
    Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005; 23:307336.
  • 51
    Le Bon A, Thompson C, Kamphuis E et al. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol 2006; 176:20742078.
  • 52
    Proietti E, Bracci L, Puzelli S et al. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol 2002; 169:375383.